Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by X Square Capital LLC

X Square Capital LLC trimmed its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 72.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 61,182 shares of the company's stock after selling 158,981 shares during the quarter. X Square Capital LLC's holdings in Teva Pharmaceutical Industries were worth $1,348,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. FMR LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 49.5% during the third quarter. FMR LLC now owns 62,740,763 shares of the company's stock valued at $1,130,589,000 after purchasing an additional 20,762,226 shares in the last quarter. Janus Henderson Group PLC lifted its stake in Teva Pharmaceutical Industries by 7,945.2% during the 3rd quarter. Janus Henderson Group PLC now owns 4,791,937 shares of the company's stock valued at $86,350,000 after acquiring an additional 4,732,374 shares during the period. Clal Insurance Enterprises Holdings Ltd boosted its holdings in shares of Teva Pharmaceutical Industries by 12.8% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock valued at $859,935,000 after acquiring an additional 4,418,961 shares during the last quarter. Todd Asset Management LLC bought a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter worth approximately $58,243,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Teva Pharmaceutical Industries by 237.5% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,377,517 shares of the company's stock valued at $60,863,000 after purchasing an additional 2,376,668 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Remove Ads

Teva Pharmaceutical Industries Trading Down 0.0 %

TEVA traded down $0.01 during trading on Tuesday, reaching $15.37. The company had a trading volume of 2,750,167 shares, compared to its average volume of 9,662,382. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The business has a 50 day simple moving average of $17.08 and a 200-day simple moving average of $18.11. The stock has a market cap of $17.42 billion, a P/E ratio of -10.61, a PEG ratio of 1.44 and a beta of 0.82. Teva Pharmaceutical Industries Limited has a 52 week low of $12.51 and a 52 week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, equities analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

TEVA has been the topic of several research reports. StockNews.com cut shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a report on Thursday, March 27th. Bank of America dropped their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. Piper Sandler increased their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a report on Friday, January 17th. UBS Group reduced their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. Finally, Barclays cut their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, January 30th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $23.43.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.